Home > Browse Issues > Vol.41 No.4

The Expression Dynamics of PAUF in Ovarian Cancer and Its Relationship with TLR4/MyD88 Signaling Pathway


Zhou Caihong1, Zhou Caixia2

(1Obstetrics and gynecology department, The People’s Hsopital of Dongying District, Dongying 257000, China; 2Obstetrics and gynecology department, The Second People’s Hospital of Dongying, Dongying 257335, China)
Abstract:

The expression dynamics of pancreatic adenocarcinoma up-regulated factor (PAUF) in ovarian cancer and to explore its potential relationship with TLR4/MyD88 signaling pathway in ovarian cancer are discussed in this paper. A total of 217 patients with ovarian cancer in our hospital from October 2014 to May 2016 were involved in the ovarian cancer group. Meanwhile, another 45 patients with ovarian benign tumor were assigned into the benign group and another 52 health persons were assigned into the control group. The expression level of PAUF, TLR4 and MyD88 in the ovarian organism were measured by immunohistochemical staining (IHC). The expression level of PAUF, TLR4 and MyD88 were compared among three groups. The relationship between PAUF and TLR4 or MyD88 were analyzed. The clinical factors affecting PAUF, TLR4 and MyD88 expression were analyzed. The results indicated that PAUF, TLR4 and MyD88 were significantly highly expressed in tissues from ovarian cancer group when compared to benign tumor group and control group (P<0.05). The positive correlation between PAUF and TLR4 (r=0.521, P<0.001) or MyD88 (r=0.581, P<0.001) were observed. PAUF expression were affected by tumor types, FIGO classification and cell differentiation (P<0.05). But TLR4 expression was only affected by cell differentiation (P<0.05) and tumor types had effect on MyD88 expression (P<0.05). The results indicated that PAUF was highly expressed in tissues from patients with ovarian cancer, and its expression was positively correlated with TLR4 and MyD88 expression. Thus, PAUF might be involved in TLR4/MyD88 signaling pathway in the incidence and development of ovarian cancer.



CSTR: 32200.14.cjcb.2019.04.0015